CClinicalTrials.gg
CompletedNCT01238263Updated Nov 10, 2010

Autologous Serum Skin Testing in Patients With Atopic Dermatitis Autologous Serum Skin Testing in Patients With Atopic Dermatitis

An observational study in Atopic Dermatitis, Serum Skin Test, sponsored by Yuzuncu Yıl University. Completed. Open to participants aged 1 Year to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-11-10.

Sponsored by Yuzuncu Yıl University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
90
Ages
1 Year to 45 Years
Sex
All
01

Study summary

Recently, IgE-type autoantibodies against self proteins have been detected in the serum of the atopic dermatitis patients. The role of this IgE autoantibodies involved in the pathogenesis of atopic dermatitis is not known, yet. But, there may be a correlation between the severity of the disease and the serum levels of this autoantibodies. The autologous serum skin testing is applied to both atopic dermatitis patients and healthy control and the results are estimated in this study.The investigators detected 70% positive autologous serum skin testing in atopic dermatitis patients and test positivity was higher in patients with atopy history, moderately severe disease calculated by SCORAD index and high serum IgE levels.

02

Conditions studied

  • Atopic Dermatitis, Serum Skin Test

Keywords

  • Atopic dermatitis, autologous serum skin testing, IgE autoantibodies
03

In context

Dermatitis, Atopic

1,419 studies on the registry are indexed under Dermatitis, Atopic; 258 are open to participants now.

This study's enrollment of 90 is below the median of 150 across 237 observational studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

Yuzuncu Yıl University is the lead sponsor of 124 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

90

Inclusion criteria

  • Sixty AD patients and 30 healthy individuals

Exclusion criteria

Exclusion Criteria:

  • . The patients showing evidence of any other disease are not included to our study. No drug was allowed fourteen days prior to the test, including antihistamines and steroids.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
90 participants (actual)
06

Study locations

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 10, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01238263
Lead sponsor
Yuzuncu Yıl University
First posted
Nov 10, 2010
Start date
Apr 2009
Primary completion
Jun 2010
Completion
Aug 2010
Last update
Nov 10, 2010

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion